Table 4.
Agents targeting the EGFR family under investigation or approved for metastatic breast cancer
Agent | Class of agent | Target | Stage of development in breast cancer |
Trastuzumab | Monoclonal antibody | HER2 | Approved |
Lapatinib | TKI | EGFR, HER2 | Approved |
Erlotinib | TKI | EGFR | II |
Cetuximab | Monoclonal antibody | EGFR | II |
Gefitinib | TKI | EGFR | Discontinued |
EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitor.